Sidney Kimmel Cancer Center LAPS Institutional Collaboration

悉尼金梅尔癌症中心 LAPS 机构合作

• 批准号: 9886229
• 负责人: Steven Cohen
• 金额: $ 39.85万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9886229
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Basic Science; Cancer Biology; Cancer Center; Catchment Area; Characteristics; Cities; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical assessments; Collaborations; Communities; Complement; County; Delaware; Discipline; Eastern Cooperative Oncology Group; Education; Faculty; Fostering; Funding Opportunities; Goals; Health; Health system; Hospitals; Incidence; Industry; Infrastructure; Institution; Knowledge; Laboratories; Laboratory Research; Lead; Leadership; Malignant Neoplasms; NCI Center for Cancer Research; NCI-Designated Cancer Center; National Clinical Trials Network; New Jersey; Oncology; Oncology Group; Outreach Research; Participant; Patients; Pennsylvania; Philadelphia; Population Heterogeneity; Population Research; Positioning Attribute; Process; Protocols documentation; Radiation Therapy Oncology Group; Research; Research Personnel; Research Priority; Role; Shapes; Site; System; Technology; Time; Translational Research; Underserved Population; United States National Institutes of Health; base; bench to bedside; cancer care; career development; data quality; design; health equity; innovation; leadership development; member; mortality; outreach; performance site; population based; programs; rare cancer; research study; socioeconomics; symptom management

ABSTRACT The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is a NCI-designated cancer center nucleated at the Jefferson Health-Center City campus and enriched by fully integrated research components at Jefferson Health-Abington and Jefferson Health-Aria. Building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery. The Jefferson Health system has expanded over the last 3 years and now includes a system of 12 Hospitals treating more than 8,000 new cancer cases annually. The SKCC catchment area includes Philadelphia, Montgomery, and Delaware counties in Pennsylvania, and Camden County in New Jersey. Philadelphia's highly diverse population, with numerous socioeconomic, racial, and health challenges characteristic of major northeastern cities, shapes SKCC research priorities and outreach. At any given time, hundreds of research studies are underway at the cancer center, ranging from basic laboratory research to clinical assessments of new treatments to meet the needs of this diverse population. Many of these studies are collaborative, involving other cancer centers or other partners in industry and the community. The overall objective and goal of this proposal is to enable SKCC to participate as a Lead Academic Participating Site (LAPS) in the NCI National Clinical Trial Network (NCTN) Clinical Research Program. This goal will be achieved through providing scientific leadership for development and execution of NCTN trials complemented by an integrated and collaborative research program. The SKCC has an established and well supported infrastructure to nurture discoveries and processes that advance our fundamental knowledge of cancer biology and implementing them into the community. As an NCI-designated Cancer Center, SKCC addresses the cancer needs of a diverse population through integration of laboratory and population-based clinical research, engagement of the community in relevant research to identified challenges, outreach, and education regarding clinical trials. We propose the following specific aims in this LAPS application: Specific Aim 1: Deliver and enhance access to the most advanced cancer care through participation and dissemination of NCTN initiatives including trials for rare tumors across the SKCC. Specific Aim 2: Promote and support the scientific leadership within the NCTN. Specific Aim 3: To foster junior faculty investigators' career development through NCTN participation in both NCTN/NCI committee engagement and as key contributors to conceptual protocol designs.

抽象的 西德尼·金梅尔癌症中心（SKCC）的总体目标是利用研究专业知识来减少 大费城及以后的癌症的总体发病率，负担和死亡率。 SKCC目标是 通过独特的优势实现，通过跨基本，临床的协作解决癌症问题 和人口研究学科。 SKCC是在杰斐逊（Jefferson）核定的NCI指定的癌症中心 卫生中心城市校园，由杰斐逊健康 - 阿宾顿的完全集成的研究组件丰富 和杰斐逊健康 - 阿里亚。在这些优势的基础上，SKCC专注于满足集水区需求 通过培养跨学科研究，扩大创新研究能力，扩展外展 以及对社区的临床研究，并提高基准对床的发现的速度。这 杰斐逊卫生系统在过去3年中一直在扩展，现在包括一个由12家医院组成的系统 每年治疗8,000多个新癌症病例。 SKCC集水区包括费城， 宾夕法尼亚州的蒙哥马利和特拉华州县，以及新泽西州的卡姆登县。费城的 高度多样化的人口，具有众多社会经济，种族和健康挑战的特征 东北城市，塑造SKCC研究的重点和外展。在任何给定时间，数百个研究 癌症中心正在进行研究，从基本实验室研究到临床评估 新的治疗方法可以满足这种不同人群的需求。这些研究中有许多是协作的，涉及 其他癌症中心或行业和社区的其他伙伴。总体目标和目标 提案将使SKCC能够作为NCI National的主要学术参与地点（LAPS）参与 临床试验网络（NCTN）临床研究计划。这个目标将通过提供 由综合和 协作研究计划。 SKCC拥有建立良好支持的基础设施以培育 发现和过程可以提高我们对癌症生物学的基本知识并实施它们 进入社区。作为NCI指定的癌症中心，SKCC满足了多种多​​样的癌症需求 通过整合实验室和基于人群的临床研究的人口，参与 有关临床试验的挑战，外展和教育的相关研究社区。我们 提出以下特定目的在此圈申请中：特定目标1：交付和增强访问权限 通过参与和传播NCTN计划的最先进的癌症护理，包括 跨SKCC的罕见肿瘤。特定目的2：促进和支持科学领导 NCTN。特定目标3：通过NCTN参与来培养初级教师调查员的职业发展 在NCTN/NCI委员会的参与和作为概念协议设计的关键因素中。